Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse

enthalten in: Neuro-Oncology | January 2022

von Richardson, S. | Hill, R. | Kui, C. | +27

MB-49INTENSIVE TREATMENT OF HIGH-RISK MEDULLOBLASTOMA (HR-MB): HOW TO LEARN FROM TOXICITIES IN AN EUROPEAN SETTING OF RADIOTHERAPISTS AND PHYSICISTS OF THE SIOP BRAIN TUMOR WORKING GROUP

enthalten in: Neuro-Oncology | 2016

von Gandola, L. | Horan, G. | Meroni, S. | +18

MB-47RISK OF HIPPOCAMPAL REGION METASTASIS IN HIGH RISK MEDULLOBLASTOMA: SUFFICIENT RATIONAL FOR HIPPOCAMPAL SPARING DURING CRANIOSPINAL IRRADIATION?

enthalten in: Neuro-Oncology | 2016

von Padovani, L. | Chapon, F. | Geoffray, A. | +16

MB-106PROGNOSTIC RELEVANCE OF CLINICAL AND MOLECULAR RISK FACTORS IN CHILDREN WITH HIGH-RISK MEDULLOBLASTOMA TREATED IN THE FRENCH PROSPECTIVE TRIAL PNET HR + 5

enthalten in: Neuro-Oncology | 2016

von Dufour, C. | Geoffray, A. | Faivre, L. | +18

EPT-13RAPIRI I – PHASE I STUDY OF DAILY ORAL RAPAMYCIN AND INTRAVENOUS IRINOTECAN IN CHILDREN WITH A RECURRENT/REFRACTORY MALIGNANT SOLID TUMOR: GOOD TOLERANCE AND PROMISING RESULTS IN BRAIN TUMORS - A REPORT FROM THE SOCIÉTÉ FRANÇAISE DES CANCERS ET LEUCÉMIES DE L'ENFANT ET DE L'ADOLESCENT (SFCE)

enthalten in: Neuro-Oncology | 2016

von Jannier, S. | Kemmel, V. | Koob, M. | +11